AKO004

**AKO004** is an investigational, preclinical psychedelic combination formulation developed by Akome Biotech for **Parkinson's disease**. It combines N,N-dimethyltryptamine with an undisclosed naturally occurring plant bioactive. Akome has described the program as having potential antioxidant and neuroprotective effects, including suppression of oxidative stress, enhancement of intracellular antioxidant defenses, and possible preservation of neuronal structure or function; however, the specific plant-derived component, molecular targets, route, dosage form, and definitive mechanism have not been publicly disclosed. ([webfiles.thecse.com](https://webfiles.thecse.com/07262021_COOL_PR_AKO004_Parkinson.pdf))